Label: ARESTIN- minocycline hydrochloride powder

  • NDC Code(s): 65976-100-01, 65976-100-12, 65976-100-24
  • Packager: OraPharma, Inc.
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: New Drug Application

Drug Label Information

Updated December 15, 2017

If you are a consumer or patient please visit this version.

  • SPL UNCLASSIFIED SECTION

    Rx only

    Close
  • DESCRIPTION

    ARESTIN (minocycline hydrochloride) microspheres, 1 mg is a subgingival sustained-release product containing the antibiotic minocycline hydrochloride incorporated into a bioresorbable polymer, Poly (glycolide-co-dl-lactide) or PGLA, for professional subgingival administration into periodontal pockets. Each unit-dose cartridge delivers minocycline hydrochloride equivalent to 1 mg of minocycline free base.

    The molecular formula of minocycline hydrochloride is C23H27N3O7 ·HCl, and the molecular weight is 493.94. The structural formula of minocycline hydrochloride is:

    image-01.jpg
    Close
  • CLINICAL PHARMACOLOGY

    Mechanism of Action

    The mechanism of action of ARESTIN as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis is unknown.

    Microbiology

    Minocycline, a member of the tetracycline class of antibiotics, has a broad spectrum of activity. It is bacteriostatic and exerts its antimicrobial activity by inhibiting protein synthesis. In vitro susceptibility testing has shown that the organisms Porphyromonas gingivalis, Prevotella intermedia, Fusobacterium nucleatum, Eikenella corrodens, and Actinobacillus actinomycetemcomitans, which are associated with periodontal disease, are susceptible to minocycline at concentrations of ≤8 mcg/mL; qualitative and quantitative changes in plaque microorganisms have not been demonstrated in subjects with periodontitis, using this product.

    The emergence of minocycline-resistant bacteria in single-site plaque samples was studied in subjects before and after treatment with ARESTIN at 2 centers. There was a slight increase in the numbers of minocycline-resistant bacteria at the end of the 9-month study period; however, the number of subjects studied was small and the clinical significance of these findings is unknown.

    The emergence of minocycline-resistant bacteria and changes in the presence of Candida albicans and Staphylococcus aureus in the gastrointestinal tract were studied in subjects treated with ARESTIN in one phase 3 study. No changes in the presence of minocycline-resistant bacteria or Candida albicans or Staphylococcus aureus were seen at the end of the 56-day study period.

    Pharmacokinetics

    In a pharmacokinetic study, 18 subjects (10 men and 8 women) with moderate to advanced chronic periodontitis were treated with a mean dose of 46.2 mg (25 to 112 unit doses) of ARESTIN. After fasting for at least 10 hours, subjects received subgingival application of ARESTIN (1 mg per treatment site) following scaling and root planing at a minimum of 30 sites on at least 8 teeth. Investigational drug was administered to all eligible sites ≥5 mm in probing depth. Mean dose normalized saliva AUC and Cmax were found to be approximately 125 and 1000 times higher than those of serum parameters, respectively.

    Clinical Studies

    In 2 well-controlled, multicenter, investigator-blind, vehicle-controlled, parallel-design studies (3 arms), 748 subjects (study OPI-103A=368, study OPI-103B=380) with generalized moderate to advanced adult periodontitis characterized by a mean probing depth of 5.90 and 5.81 mm, respectively, were enrolled. Subjects received 1 of 3 treatments: (1) scaling and root planing (SRP), (2) SRP + vehicle (bioresorbable polymer, PGLA), and (3) SRP + ARESTIN. To qualify for the study, subjects were required to have 4 teeth with periodontal pockets of 6 to 9 mm that bled on probing. However, treatment was administered to all sites with mean probing depths of 5 mm or greater. Subjects studied were in good general health. Subjects with poor glycemic control or active infectious diseases were excluded from the studies. Retreatment occurred at 3 and 6 months after initial treatment, and any new site with pocket depth ≥5 mm also received treatment. Subjects treated with ARESTIN were found to have statistically significantly reduced probing pocket depth compared with those treated with SRP alone or SRP + vehicle at 9 months after initial treatment, as shown in Table 1.

    Table 1: Probing Pocket Depth at Baseline and Change in Pocket Depth at 9 Months from 2 Multicenter US Clinical Trials
    Time Study OPI-103A
    N=368
    Study OPI-103B
    N=380
    SRP
    Alone
    n=124
    SRP +
    Vehicle n=123
    SRP + ARESTIN n=121 SRP
    Alone
    n=126
    SRP +
    Vehicle n=126
    SRP + ARESTIN n=128
    SE = standard error; SRP = scaling and root planing; PD = pocket depth
    Significantly different from SRP: *(P ≤0.05); **(P ≤0.001)
    Significantly different from SRP + vehicle: ††(P ≤0.001)

    PD (mm) at Baseline

    5.88
    ±0.04

    5.91
    ±0.04

    5.88
    ±0.04

    5.79
    ±0.03

    5.82
    ±0.04

    5.81
    ±0.04

    [Mean ± SE]

    PD (mm) Change from Baseline at 9
    Months [Mean ± SE]

    -1.04
    ±0.07

    -0.90

    ±0.54

    -1.20*††

    ±0.07

    -1.32

    ±0.07

    -1.30

    ±0.07

    -1.63**††

    ±0.07

    In these 2 studies, an average of 29.5 (5-114), 31.7 (4-137), and 31 (5-108) sites were treated at baseline in the SRP alone, SRP + vehicle, and SRP + ARESTIN groups, respectively. When these studies are combined, the mean pocket depth change at 9 months was -1.18 mm, -1.10 mm, and -1.42 mm for SRP alone, SRP + vehicle, and SRP + ARESTIN, respectively.

    Table 2: Numbers (Percentage) of Pockets Showing a Change of Pocket Depth ≥2 mm at 9 Months from 2 Multicenter US Clinical Trials
                             Study OPI-103A Study OPI-103B
    SRP
    Alone
    SRP +
    Vehicle
    SRP + ARESTIN SRP
    Alone
    SRP +
    Vehicle
    SRP + ARESTIN

    Pockets

    1046

    (31.1%)

    927

    (25.7%)

    1326

    (36.5%)

    1692

    (42.2%)

    1710

    (40.0%)

    2082

    (51.0%)

    ≥2 mm
    (% of Total)

    Pockets

    417

    (12.4%)

    315

    (8.7%)

    548

    (15.1%)

    553

    (13.8%)

    524

    (12.3%)

    704

    (17.3%)

    ≥3 mm
    (% of Total)

    SRP + ARESTIN resulted in a greater percentage of pockets showing a change of PD ≥2 mm and ≥3 mm compared to SRP alone at 9 months, as shown in Table 2.

    Table 3: Mean Pocket Depth Changes (SE) in Subpopulations, Studies 103A and 103B Combined

    SRP
    Alone

    SRP +
    Vehicle

    SRP +
    ARESTIN

    Smokers

    n=91
    -0.96 (±0.09) mm

    n=90
    -0.98 (±0.07) mm

    n=90
    -1.24 (±0.09) mm**

    Nonsmokers

    n=159
    -1.31 (±0.06) mm

    n=159
    -1.17 (±0.07) mm

    n=159
    -1.53 (±0.06) mm**

    Subjects >50 YOA

    n=21
    -1.07 (±0.09) mm

    n=81
    -0.92 (±0.08) mm

    n=107
    -1.42 (±0.08) mm**

    Subjects ≤50 YOA

    n=167
    -1.24 (±0.06) mm

    n=168
    -1.19 (±0.06) mm

    n=142
    -1.43 (±0.07) mm*

    Subjects with CV Disease

    n=36
    -0.99 (±0.13) mm

    n=29
    -1.06 (±0.14) mm

    n=36
    -1.56 (±0.14) mm**

    Subjects without CV Disease

    n=214
    -1.22 (±0.06) mm

    n=220
    -1.11 (±0.05) mm

    n=213
    -1.40 (±0.06) mm**

    SRP = scaling and root planing; YOA = years of age; CV = cardiovascular
    *SRP vs SRP + ARESTIN P ≤0.05; **SRP vs SRP + ARESTIN P ≤0.001

    In both studies, the following patient subgroups were prospectively analyzed: smokers, subjects over and under 50 years of age, and subjects with a previous history of cardiovascular disease. The results of the combined studies are presented in Table 3.

    In smokers, the mean reduction in pocket depth at 9 months was less in all treatment groups than in nonsmokers, but the reduction in mean pocket depth at 9 months with SRP + ARESTIN was significantly greater than with SRP + vehicle or SRP alone.

    Table 4: Mean Pocket Depth Change in Subjects with Mean Baseline PD ≥5 mm, ≥6 mm, and ≥7 mm at 9 Months from 2 Multicenter US Clinical Trials
                             Study OPI-103A Study OPI-103B
    Mean Baseline
    Pocket Depth
    SRP
    Alone
    SRP + Vehicle SRP + ARESTIN SRP
    Alone
    SRP + Vehicle SRP + ARESTIN
    *
    Statistically significant comparison between SRP + ARESTIN and SRP alone

    ≥5 mm
    (n)

    -1.04 mm

    (124)

    -0.90 mm

    (123)

    -1.20 mm*

    (121)

    -1.32 mm

    (126)

    -1.30 mm

    (126)

    -1.63 mm*

    (128)

    ≥6 mm
    (n)

    -0.91 mm

    (34)

    -0.77 mm

    (46)

    -1.40 mm*

    (45)

    -1.33 mm

    (37)

    -1.46 mm

    (40)

    -1.69 mm*

    (25)

    ≥7 mm
    (n)

    -1.10 mm

    (4)

    -0.46 mm

    (5)

    -1.91 mm

    (3)

    -1.72 mm

    (3)

    -1.11 mm

    (3)

    -2.84 mm

    (2)

    The combined data from these 2 studies also show that for pockets 5 mm to 7 mm at baseline, greater reductions in pocket depth occurred in pockets that were deeper at baseline.

    Close
  • INDICATIONS AND USE

    ARESTIN is indicated as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN may be used as part of a periodontal maintenance program which includes good oral hygiene and scaling and root planing.

    Close
  • CONTRAINDICATIONS

    ARESTIN should not be used in any patient who has a known sensitivity to minocycline or tetracyclines.

    Close
  • WARNINGS

    THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT (LAST HALF OF PREGNANCY, INFANCY, AND CHILDHOOD TO THE AGE OF 8 YEARS) MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH (YELLOW-GRAY BROWN). This adverse reaction is more common during long-term use of the drugs, but has been observed following repeated short-term courses. Enamel hypoplasia has also been reported. TETRACYCLINE DRUGS, THEREFORE, SHOULD NOT BE USED IN THIS AGE GROUP, OR IN PREGNANT OR NURSING WOMEN, UNLESS THE POTENTIAL BENEFITS ARE CONSIDERED TO OUTWEIGH THE POTENTIAL RISKS. Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryotoxicity has also been noted in animals treated early in pregnancy. If any tetracyclines are used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of skin erythema.

    Close
  • PRECAUTIONS

    Hypersensitivity Reactions and Hypersensitivity Syndrome

     
    The following adverse events have been reported with minocycline products when taken orally. Hypersensitivity reactions and hypersensitivity syndrome that included, but were not limited to anaphylaxis, anaphylactoid reaction, angioneurotic edema, urticaria, rash, eosinophilia, and one or more of the following: hepatitis, pneumonitis, nephritis, myocarditis, and pericarditis may be present. Swelling of the face, pruritus, fever and lymphadenopathy have been reported with the use of ARESTIN. Some of these reactions were serious. Post-marketing cases of anaphylaxis and serious skin reactions such as Stevens-Johnson syndrome and erythema multiforme have been reported with oral minocycline.

    Autoimmune Syndromes

     
    Tetracyclines, including oral minocycline, have been associated with the development of autoimmune syndromes including a lupus-like syndrome manifested by arthralgia, myalgia, rash, and swelling. Sporadic cases of serum sickness-like reaction have presented shortly after oral minocycline use, manifested by fever, rash, arthralgia, lymphadenopathy and malaise. In symptomatic patients, liver function tests, ANA, CBC, and other appropriate tests should be performed to evaluate the patients. No further treatment with ARESTIN should be administered to the patient.

    The use of ARESTIN in an acutely abscessed periodontal pocket has not been studied and is not recommended.

    While no overgrowth by opportunistic microorganisms, such as yeast, was noted during clinical studies, as with other antimicrobials, the use of ARESTIN may result in overgrowth of non-susceptible microorganisms including fungi. The effects of treatment for greater than 6 months have not been studied.

    ARESTIN should be used with caution in patients having a history of predisposition to oral candidiasis. The safety and effectiveness of ARESTIN have not been established for the treatment of periodontitis in patients with coexistent oral candidiasis.

    ARESTIN has not been clinically tested in immunocompromised patients (such as those immunocompromised by diabetes, chemotherapy, radiation therapy, or infection with HIV).

    If superinfection is suspected, appropriate measures should be taken.

    ARESTIN has not been clinically tested in pregnant women.

    ARESTIN has not been clinically tested for use in the regeneration of alveolar bone, either in preparation for or in conjunction with the placement of endosseous (dental) implants or in the treatment of failing implants.

    Information for Patients

    After treatment, patients should avoid chewing hard, crunchy, or sticky foods (i.e., carrots, taffy, and gum) with the treated teeth for 1 week, as well as avoid touching treated areas. Patients should also postpone the use of interproximal cleaning devices around the treated sites for 10 days after administration of ARESTIN. Patients should be advised that although some mild to moderate sensitivity is expected during the first week after SRP and administration of ARESTIN, they should notify the dentist promptly if pain, swelling, or other problems occur. Patients should be notified to inform the dentist if itching, swelling, rash, papules, reddening, difficulty breathing, or other signs and symptoms of possible hypersensitivity occur.

    Carcinogenicity, Mutagenicity, Impairment of Fertility

    Dietary administration of minocycline in long-term tumorigenicity studies in rats resulted in evidence of thyroid tumor production. Minocycline has also been found to produce thyroid hyperplasia in rats and dogs. In addition, there has been evidence of oncogenic activity in rats in studies with a related antibiotic, oxytetracycline (i.e., adrenal and pituitary tumors). Minocycline demonstrated no potential to cause genetic toxicity in a battery of assays which included a bacterial reverse mutation assay (Ames test), an in vitro mammalian cell gene mutation test (L5178Y/TK+/- mouse lymphoma assay), an in vitro mammalian chromosome aberration test, and an in vivo micronucleus assay conducted in ICR mice.

    Fertility and general reproduction studies have provided evidence that minocycline impairs fertility in male rats.

    Pregnancy

    Teratogenic Effects: (See WARNINGS.)

    Labor and Delivery

    The effects of tetracyclines on labor and delivery are unknown.

    Nursing Mothers

    Tetracyclines are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from the tetracyclines, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother (see WARNINGS).

    Pediatric Use

    Since adult periodontitis does not affect children, the safety and effectiveness of ARESTIN in pediatric patients cannot be established.

    Close
  • ADVERSE REACTIONS

    The most frequently reported non-dental, treatment-emergent adverse events in the 3 multicenter US trials were headache, infection, flu syndrome, and pain.

    Table 5: Adverse Events (AEs) Reported in ≥3% of the Combined Clinical Trial Population of 3 Multicenter US Trials by Treatment Group
    SRP
    Alone
    N=250
    SRP +
    Vehicle
    N=249
    SRP +
    ARESTIN®
    N=423

    Number (%) of Subjects Treatment-emergent AEs

    62.4%

    71.9%

    68.1%

    Total Number of AEs

    543

    589

    987

      Periodontitis

    25.6%

    28.1%

    16.3%

      Tooth Disorder

    12.0%

    13.7%

    12.3%

      Tooth Caries

    9.2%

    11.2%

    9.9%

      Dental Pain

    8.8%

    8.8%

    9.9%

      Gingivitis

    7.2%

    8.8%

    9.2%

      Headache

    7.2%

    11.6%

    9.0%

      Infection

    8.0%

    9.6%

    7.6%

      Stomatitis

    8.4%

    6.8%

    6.4%

      Mouth Ulceration

    1.6%

    3.2%

    5.0%

      Flu Syndrome

    3.2%

    6.4%

    5.0%

      Pharyngitis

    3.2%

    1.6%

    4.3%

      Pain

    4.0%

    1.2%

    4.3%

      Dyspepsia

    2.0%

    0

    4.0%

      Infection Dental

    4.0%

    3.6%

    3.8%

      Mucous Membrane Disorder

    2.4%

    0.8%

    3.3%

    The change in clinical attachment levels was similar across all study arms, suggesting that neither the vehicle nor ARESTIN compromise clinical attachment.

    To report SUSPECTED ADVERSE REACTIONS, contact Valeant Pharmaceuticals North America LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    Close
  • DOSAGE AND ADMINISTRATION

    ARESTIN is provided as a dry powder, packaged in a unit-dose cartridge with a deformable tip (see Figure 1), which is inserted into a spring-loaded cartridge handle mechanism (see Figure 2) to administer the product.

    The oral health care professional removes the disposable cartridge from its pouch and connects the cartridge to the handle mechanism (see Figures 3 - 4). ARESTIN is a variable dose product, dependent on the size, shape, and number of pockets being treated. In US clinical trials, up to 122 unit-dose cartridges were used in a single visit and up to 3 treatments, at 3-month intervals, were administered in pockets with pocket depth of 5 mm or greater.

    Arestin figures.jpg

    The administration of ARESTIN does not require local anesthesia. Professional subgingival administration is accomplished by inserting the unit-dose cartridge to the base of the periodontal pocket and then pressing the thumb ring in the handle mechanism to expel the powder while gradually withdrawing the tip from the base of the pocket. The handle mechanism should be sterilized between patients. ARESTIN does not have to be removed, as it is bioresorbable, nor is an adhesive or dressing required.

    Close
  • HOW SUPPLIED

    ARESTIN® (minocycline hydrochloride) microspheres, 1 mg is supplied as follows:

    NDC 65976-100-01 1 unit-dose cartridge with desiccant in a heat-sealed, foil-laminated pouch

    NDC 65976-100-24 12 unit-dose cartridges in 1 tray with desiccant in a heat-sealed, foil-laminated, resealable pouch. There are 2 pouches in each box.

    Each unit-dose cartridge contains the product identifier "OP-1."

    Storage Conditions

    Store at 20° to 25°C (68° to 77°F)/60% RH: excursions permitted to 15° to 30°C (59° to 86°F). Avoid exposure to excessive heat.

    Close
  • SPL UNCLASSIFIED SECTION

    Manufactured for:

    OraPharma, a division of Valeant Pharmaceuticals North America LLC
    Bridgewater, NJ 08807 USA

    U.S. Patent Numbers: 6,682,348 and 7,699,609

    Arestin is a trademark of Valeant Pharmaceuticals International, Inc. or its affiliates.

    ©Valeant Pharmaceuticals North America LLC

    Rev. 12/2017

    9546402
    20001545C

    Close
  • PRINCIPAL DISPLAY PANEL - 1 mg Carton

    NDC 65976-100-24

    Microsphere Delivery System
    Arestin®
    minocycline HCl 1mg
    MICROSPHERES

    Store at 20° to 25°C (68° to 77°F)
    /60% RH: excursions permitted to
    15° to 30°C (59° to 86°F).

    Avoid exposure to excessive heat

    For Subgingival Application

    Rx only

    To order: Call 1-866-ARESTIN (273-7846)
    or visit our Web site at www.ArestinProfessional.com

    oraPHARMA

    2 resealable foil pouches
    12 cartridges per pouch
    1 mg of minocycline per cartridge

    Arestin-carton.jpg
    Close
  • Principal Display Panel – 1 mg pouch containing 1 cartridge

    Microsphere Delivery System
    Arestin®
    minocycline HCl 1 mg
    MICROSPHERES

    For use only with the patient listed on the prescription label. Rx Pack: Not for dental professional resale

    For Subgingival Application
    Rx only
    Pouch contains 1 cartridge
    Cartridge contains 1 mg minocycline

    For more information, call 1-866-ARESTIN
    (273-7846) or visit www.ArestinProfessional.com

    Manufactured for:
    OraPharma, a division of
    Valeant Pharmaceuticals North America LLC
    Bridgewater, NJ 08807 USA

    ©Valeant Pharmaceuticals North America LLC

    Usual Dosage: Please see accompanying
    full Prescribing Information.

    arestincarton.jpg
    Close
  • INGREDIENTS AND APPEARANCE
    ARESTIN 
    minocycline hydrochloride powder
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:65976-100
    Route of Administration ORAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    Minocycline Hydrochloride (UNII: 0020414E5U) (Minocycline - UNII:FYY3R43WGO) Minocycline 1 mg
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:65976-100-01 1 in 1 POUCH; Type 0: Not a Combination Product 03/21/2011
    2 NDC:65976-100-12 1 in 1 BOX 03/21/2011
    2 1 in 1 POUCH
    2 12 in 1 TRAY; Type 0: Not a Combination Product
    3 NDC:65976-100-24 2 in 1 BOX 03/21/2011
    3 1 in 1 POUCH
    3 12 in 1 TRAY; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA050781 03/21/2011
    Labeler - OraPharma, Inc. (075846118)
    Registrant - Valeant Pharmaceuticals North America LLC (042230623)
    Establishment
    Name Address ID/FEI Business Operations
    Alcami Carolinas Corporation 832395235 MANUFACTURE(65976-100)
    Establishment
    Name Address ID/FEI Business Operations
    Sharp Corporation 143696495 PACK(65976-100) , LABEL(65976-100)
    Establishment
    Name Address ID/FEI Business Operations
    Valeant Pharmaceuticals International Inc. 245141858 PACK(65976-100) , LABEL(65976-100)
    Close